Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment
JCO Precision Oncology · 2026-06 · 10 (6)
DOI: 10.1200/po-25-00807 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-06. Verfasst von Sophie Moravec und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Genetic Testing, Carcinoma, Pancreatic Ductal, Point-of-Care Testing. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Pancreatic ductal adenocarcinoma (PDAC) ranks third in cancer-related deaths. Although national guidelines recommend germline multigene panel testing (MGPT) for all patients with PDAC, only 6%-19% undergo testing, mostly due to under-referral and genetic counselor shortages. We evaluated a coordinator-led and digitally supported workflow designed to increase access to pretest education, improve MGPT uptake, and reduce turnaround time (TAT) for patients newly diagnosed with PDAC at our center. METHODS Through the Genetic Information for Treatment Decisions (GIFTD) Initiative, a Genetic Risk Education Coordinator (GREC) served as a liaison between providers, genetic counselors, and patients. Subsequently, we partnered with Nest Genomics to develop the GIFTD Partially Automated Nest Copilot (G-PANC), a digital tool that collects cancer history, delivers genetic education, and assesses MGPT interest before coordinator follow-up. Outcomes included genetic education completion, MGPT uptake, and TAT across sequential phases (baseline, GREC-only, and G-PANC [GREC+ Nest Copilot]). RESULTS Over 1 year, 354 patients with PDAC were invited to access G-PANC; 73% activated accounts, 80% completed education, and 63% expressed MGPT interest. Among those completing education, 86% engaged with the GREC, and 81% consented to testing, including 15 initially uninterested patients. Of the 127 patients tested, 13% had pathogenic variants. Compared with a baseline/traditional workflow, the GREC-only phase was associated with increased MGPT uptake (43% to 80%) and reduced TAT (54 to 30 days). During the subsequent G-PANC phase, testing uptake remained high (77%) and TAT further decreased to 22 days. CONCLUSION A coordinator-led workflow substantially increased MGPT uptake and reduced TAT. Digital education integration was feasible, maintained high testing rates, and reduced TAT. Prospective evaluation will clarify the independent contributions of digital automation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL.
- Department of Pathology, Moffitt Cancer Center, Tampa, FL.
- Nest Genomics, New York, NY.
- Healthcare Delivery Research Network, MedStar Health Research Institute, Washington, DC.
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL.
- Office of Community Outreach and Engagement, Moffitt Cancer Center, Tampa, FL.
ORCID-Profile: Jessica N Rivera Rivera, Toni Basinski, Nicole Nardella, Carmelo J Blanquicett, Satish S Maharaj, Richard Kim, Tiago Biachi De Castria, Andrew J Sinnamon, Allan Lima Pereira, Teresa T Ho, J Kevin Hicks, Jennifer B Permuth
Förderung
- NCI NIH HHS
Zitieren
APA
Moravec, S., Barton, L. V., Suresh, R., Hayward, L., Schmidlen, T., Rivera, J. N. R., Basinski, T., Alhassan, S., Nardella, N., Oraiqat, A., Craig, L., Cooper, L., Blanquicett, C. J., Maharaj, S. S., Blue, K., Adams, M., Kim, R., Biachi De Castria, T., Malafa, M., …, & Permuth, J. B. (2026). Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment. JCO Precision Oncology, 10(6). https://doi.org/10.1200/po-25-00807
Vancouver
Moravec S, Barton LV, Suresh R, Hayward L, Schmidlen T, Rivera JNR, et al. Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment. JCO Precision Oncology. 2026;10(6). doi:10.1200/po-25-00807
BibTeX
@article{Moravec2026,
author = {Moravec, Sophie and Barton, Laura V and Suresh, Revathy and Hayward, Laura and Schmidlen, Tara and Rivera, Jessica N Rivera and Basinski, Toni and Alhassan, Solomon and Nardella, Nicole and Oraiqat, Adrianna and Craig, Leticia and Cooper, Laura and Blanquicett, Carmelo J and Maharaj, Satish S and Blue, Kirsten and Adams, Melissa and Kim, Richard and Biachi De Castria, Tiago and Malafa, Mokenge and Sinnamon, Andrew J and Pereira, Allan Lima and Kim, Dae Won and Hoffe, Sarah and Hodul, Pamela J and Vadaparampil, Susan T and Ho, Teresa T and Hicks, J Kevin and Snir, Moran and Permuth, Jennifer B},
title = {Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {6},
doi = {10.1200/po-25-00807}
}
EUVIMED